STOCKS | Ascletis Pharma Swings To RMB 320 Million Interim Loss

Ascletis Pharma (01672) reported an interim loss of RMB 320 million for the six months ended June 30, widening from a loss of RMB 87.951 million a year earlier, and declared no interim dividend. ETNet reported that total revenue fell 48.9% to about RMB 53 million, mainly because one-off non-recurring income, largely from government subsidies to mainland entities, declined. Administrative expenses fell 28.9%, while research and development expenses rose 130%.